RESUMO
BACKGROUND AND PURPOSE: OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in a real-life setting and to identify clinical predictors of outcome. METHODS: We designed a prospective multicentre study performed in 13 hospitals in Spain. Patients underwent a complete medical history and examination. They were treated with OnabotulinumtoxinA every 12 weeks for 1 year. Data about outcome, adverse events, abortive medication use, emergency room use and disability were collected at 3 and 12 months. RESULTS: A total of 725 subjects completed the study. At 12 months, 79.3% showed >50% reduction in number of headaches per month and 94.9% reported no adverse events. Unilaterality of pain, fewer days of disability per month and milder headache at baseline were correlated with good outcome. Duration of disease <12 months increased the chances of response to treatment with OnabotulinumtoxinA (odds ratio, 1.470; 95% confidence interval, 1.123-2.174; P = 0.045). CONCLUSIONS: This study confirmed the effectiveness of treatment with OnabotulinumtoxinA after 1 year of treatment. The chances of a good outcome may be increased by starting treatment in the first 12 months after chronic migraine diagnosis.
Assuntos
Toxinas Botulínicas Tipo A/farmacologia , Transtornos de Enxaqueca/tratamento farmacológico , Fármacos Neuromusculares/farmacologia , Avaliação de Resultados em Cuidados de Saúde , Adulto , Toxinas Botulínicas Tipo A/administração & dosagem , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares/administração & dosagem , Estudos ProspectivosRESUMO
A patient is reported who suffered from a fixed, non-progressive encephalopathy caused by a lesion involving the left portion of both the mesencephalon and basal ganglia; the lesion was caused by an acquired prenatal vascular insult. The clinical expression of third cranial nerve palsy corresponds to a nuclear syndrome of the left oculomotor nerve, affecting both eyes asymmetrically, later developing into aberrant reinnervation.
Assuntos
Blefaroptose/congênito , Dominância Cerebral/fisiologia , Embolia e Trombose Intracraniana/congênito , Regeneração Nervosa/fisiologia , Doenças do Nervo Oculomotor/congênito , Distúrbios Pupilares/congênito , Gânglios da Base/fisiopatologia , Blefaroptose/fisiopatologia , Pré-Escolar , Hemiplegia/congênito , Hemiplegia/fisiopatologia , Humanos , Embolia e Trombose Intracraniana/fisiopatologia , Masculino , Mesencéfalo/fisiopatologia , Espasticidade Muscular/congênito , Espasticidade Muscular/fisiopatologia , Exame Neurológico , Doenças do Nervo Oculomotor/fisiopatologia , Distúrbios Pupilares/fisiopatologiaRESUMO
The association of active tuberculosis with changes in the peripheral nervous system is not well defined, although it is included amongst the neuro-muscular disorders of the peripheral nerve diseases due to infective agents. We describe the case of two patients with sensory-motor polyneuropathy and coexistant active pulmonary tuberculosis which was untreated prior to diagnosis of the peripheral nervous system disorder. In both cases the condition was sub-acute and did not improve until treatment was begun. Anti-tuberculosis treatment was followed by marked improvement of both the pulmonary tuberculosis and of the polyneuropathy. The close chronological relationship of both clinical pictures with the therapeutic response supports the hypothesis of the pathogenesis of the peripheral nervous system disorder being mediated by an anomolous immune response, initiated by the infection with Koch's bacillus.
Assuntos
Doenças do Sistema Nervoso Periférico/complicações , Tuberculose Pulmonar/complicações , Adulto , Idoso , Encéfalo/fisiopatologia , Transtornos de Deglutição/etiologia , Disartria/etiologia , Feminino , Humanos , Masculino , Mycobacterium tuberculosis/isolamento & purificação , Condução Nervosa , Doenças do Sistema Nervoso Periférico/diagnóstico , Doenças do Sistema Nervoso Periférico/fisiopatologia , Nervo Fibular/fisiopatologia , Nervo Tibial/fisiopatologia , Tuberculose Pulmonar/microbiologiaRESUMO
The aim of this work has been to evaluate the epidemiologic data in a series of 157 patients operated for glioblastoma multiforme in Aragón and La Rioja, during a period of 15 years. We haven't analyzed the cases that weren't operated on, because of the localization of the tumor or the bad situation of the patient. All the patients have an anatomopathologic confirmation. We have studied a total of 795 patients operated for a cerebral or cerebellar tumor. The glioblastoma multiforme was the third type of tumor in frequency, after the meningioma and the astrocytoma. In the different groups of age the peak incidence was between the 50 and 59 years old, followed the group between 60 to 69. 153 cases appeared in adults and only 4 cases were found below the age of 20. The right hemisphere was the most frequently affected. Males were more often affected than females, with 96 cases (61.14%) in males and 61 cases (38.85%) in females. We couldn't find a significative relation between the presence of the tumor and the profession or another personal antecedent of the patients.
Assuntos
Neoplasias Encefálicas/epidemiologia , Glioblastoma/epidemiologia , Idoso , Encéfalo/patologia , Neoplasias Encefálicas/patologia , Feminino , Glioblastoma/patologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Espanha/epidemiologiaRESUMO
We have analysed the pattern of analgesic use in a group of patients that came for the first time to the neurologist. We have examined the first intention analgesic use in patients with headache, before the therapeutic intervention of the neurologist. During a month, we have followed a group of 40 patients. 20 of them were admitted as ambulatory patients at a Headache Unit at a Hospital and the other 20 were attended as outpatients by a general neurologist. 'Over-the-counter' analgesics were the most commonly used (paracetamol, acetylsalicylic acid and combinations of them with other products such as caffeine). More than a half of the patients had consumed a combination of analgesics. At the time of the investigation, the mean of analgesic use were greater in the group attended at the Headache Unit than in the one attended by the general neurologist. This could depend on the fact that chronic daily headache was more frequent in the first group and that they were older than the other group. These findings could be in relation with a larger evolution of their headache.
Assuntos
Analgésicos/uso terapêutico , Transtornos de Enxaqueca/tratamento farmacológico , Neurologia , Encaminhamento e Consulta , Doença Aguda , Adulto , Idoso , Analgésicos/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recursos HumanosAssuntos
Cefaleia Histamínica/tratamento farmacológico , Transtornos de Enxaqueca/tratamento farmacológico , Sumatriptana/uso terapêutico , Adolescente , Adulto , Idoso , Proteínas Sanguíneas/efeitos dos fármacos , Encéfalo/fisiopatologia , Cefaleia Histamínica/fisiopatologia , Feminino , Humanos , Rim/efeitos dos fármacos , Rim/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Pessoa de Meia-Idade , Transtornos de Enxaqueca/fisiopatologia , Receptores de Serotonina/efeitos dos fármacos , Sumatriptana/farmacocinética , Sumatriptana/farmacologiaRESUMO
Chronic daily headache (CDH) is a heterogeneous group of headaches that includes primary and secondary varieties. Primary CDH is a frequent entity that probably affects 4% to 5% of the population. It can be subdivided into headaches of short duration (less than 4 hours per attack), like chronic cluster headache, and disorders of long duration (greater than 4 hours per attack). Primary CDH of long duration includes transformed migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua. Analgesic or ergot overuse is frequent in all types of CDH. We review recent insights into the proposed classification, epidemiology, pathophysiology, clinical characteristics, and treatment of CDH.
Assuntos
Transtornos da Cefaleia , Adolescente , Adulto , Idoso , Analgésicos/efeitos adversos , Analgésicos/uso terapêutico , Toxinas Botulínicas Tipo A/uso terapêutico , Ensaios Clínicos como Assunto , Comorbidade , Inibidores Enzimáticos/uso terapêutico , Feminino , Predisposição Genética para Doença , Transtornos da Cefaleia/classificação , Transtornos da Cefaleia/tratamento farmacológico , Transtornos da Cefaleia/epidemiologia , Transtornos da Cefaleia/etiologia , Transtornos da Cefaleia/fisiopatologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Transtornos de Enxaqueca/induzido quimicamente , Transtornos de Enxaqueca/classificação , Transtornos de Enxaqueca/fisiopatologia , Óxido Nítrico/fisiologia , Óxido Nítrico Sintase/antagonistas & inibidores , Nociceptores/fisiologia , Prognóstico , Síndrome de Abstinência a Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/complicações , Cefaleia do Tipo Tensional/classificação , Cefaleia do Tipo Tensional/epidemiologia , Tomografia Computadorizada de Emissão , Nervo Trigêmeo/fisiopatologia , ômega-N-Metilarginina/uso terapêuticoRESUMO
Primary chronic headache can affect a patient's health-related quality of life (HQL). The Medical Outcomes Study Short Form (SF-36) questionnaire has been used to address this issue. We compare the impact of headache on the HQL of patients with migraine and chronic daily headache (CDH) using the SF-36 instrument. We analyzed a group of 115 consecutive patients; 62 migraine patients and 53 CDH patients completed the questionnaire. Patterns of disability were similar between the two groups, but CDH was marked by a lower level of health scales. Patients with CDH had a significantly worse pain score in physical functioning, role functioning (physical), bodily pain, general health perceptions, and mental health than patients with migraine headache. Our results in the migraine group were similar to findings in other publications, with the lowest scores in role functioning (physical) and bodily pain. There is no previous experience in CDH patients, but the present data suggest that the SF-36 questionnaire is valuable in determining the differences in functional status among headache types. These data suggest that the SF-36 is a reliable and valid measure of the HQL of patients with CDH, and may indeed prove to be valuable in studying the efficacy of therapeutic agents for this type of headache.
Assuntos
Cefaleia/fisiopatologia , Transtornos de Enxaqueca/fisiopatologia , Qualidade de Vida , Perfil de Impacto da Doença , Adulto , Idoso , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição da DorRESUMO
INTRODUCTION: We analysed the value of the diagnostic criteria of the International Headache Society (IHS) for the classification of the primary headaches in a headache clinic. PATIENTS AND METHODS: The IHS criteria were applied to classify 208 headaches in 194 patients. Forty-two had migraine, 18 tension type headache and 76 chronic daily headaches (CDH). RESULTS: The value of IHS criteria in order to distinguish migraine from tension type headache have a specificity of 94% and a predictive positive value of 99%. The predictive negative value is 63%. The more specific symptoms for migraine were severity, photophobia, phonofobia and vomits. IHS criteria for chronic tension type headache have a very low sensibility; only the 45% of these headaches meet criteria. If we applied the criteria of Silberstein et al we can see that, without the patient history, symptoms don't distinguish between chronic tension type headache, transformed migraine and new daily persistent headache. The most specific features for distinguishing the transformed migraine were worsening with activity, vomiting and pulsating. A 62% of the CDH have analgesic overuse. CONCLUSIONS: IHS criteria distinguish accurately between migraine and tension type headache. Symptoms do not differenciate the different kinds of CDH.